LSBCF
LakeShore Biopharma Co., Ltd.
- PER (TTM)
- -
- PER (Forward)
- -
- EPS (TTM)
- -
- EPS (Forward)
- -
- PBR
- 0.01
- 시가총액
- 1.85M
- 배당수익률
- -
- 베타
- 0.11
- 1개월 수익률
- -36.00%
- 3개월 수익률
- -82.77%
- 6개월 수익률
- -94.54%
- 1년 수익률
- -96.17%
- 2년 수익률
- -
- 5일 평균거래량
- 2297
- 60일 평균거래량
- 4145
- 1년 평균거래량
- 88513
- 5d/60d 거래량 비율
- 0.55×
- 60d/1y 거래량 비율
- 0.05×
- 변동성(60일, 연환산)
- 241.38%
- BB 스퀴즈 스코어
- 1.71
- SMA50 비율
- 0.98
- SMA200 비율
- 0.08
- RSI (14)
- 48
- 20일 수렴도
- 0.17
- 52주 최고
- 1.38
- 52주 최저
- 0.03
- 고점 대비
- -96.75%
- 저점 대비
- 61.15%
펀더멘털 갱신: 2026-05-10T09:55:27+00:00 · 시세 갱신: 2026-05-10T06:49:34+00:00
회사 정보
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine, which is in phase I trial; PIKA YS-HBV-002, an immune-therapy vaccine that is in preclinical trial for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, which are in preclinical trials. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 1994 and is based in Beijing, China.